The need for new therapies to treat coronavirus patients has prompted an onslaught of advisories from FDA clarifying how sponsors should assess and implement changes necessary to fit this new reality.
Jill Wechsler
Advertisement
Jill Wechsler is ACT's Washington Editor
Articles by Jill Wechsler
February 09, 2017
Advertisement
Latest Updated Articles
- PDUFA Offers New Tools to Support Drug Development & Review
Published: February 9th 2017 | Updated:
- FDA Speeds New Guidances to Inform Clinical Research During Pandemic
Published: June 23rd 2020 | Updated: